<DOC>
	<DOCNO>NCT02307396</DOCNO>
	<brief_summary>The main objective trial evaluate , long antipsychotic relapse-prevention continue time patient schizophrenia protect enough , withdrawal reduction medication seem appropriate . Relapse define primary outcome .</brief_summary>
	<brief_title>Evaluation Necessity Long-term Pharmacological Treatment With Antipsychotics Schizophrenic Patients</brief_title>
	<detailed_description>The main objective trial evaluate first time , long antipsychotic relapse-prevention continue time patient protect enough , guide withdrawal reduction medication seem appropriate . Relapse define primary outcome . We include patient schizophrenia schizoaffective disorder remission least 3 year stable antipsychotic medication .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Schizophrenia Spectrum Other Psychotic Disorders</mesh_term>
	<mesh_term>Perphenazine</mesh_term>
	<mesh_term>Fluphenazine</mesh_term>
	<mesh_term>Fluphenazine depot</mesh_term>
	<mesh_term>Fluphenazine enanthate</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Benperidol</mesh_term>
	<mesh_term>Bromperidol</mesh_term>
	<mesh_term>Perazine</mesh_term>
	<mesh_term>Clopenthixol</mesh_term>
	<mesh_term>Fluspirilene</mesh_term>
	<mesh_term>Pimozide</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<mesh_term>Thioridazine</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<criteria>Diagnosis schizophrenia schizoaffective disorder The participant remission least 3 year ( i.e . psychiatric hospitalisation ) stable antipsychotic medication . Remission measure use remission criterion Andreasen et al . ( 2005 ) Score ≤3 item concern psychosis `` Positive Negative Syndrom Scale '' ( PANSS ; Kay et al. , 1987 ) : `` Delusions '' ( P1 ) , `` Conceptual disorganisation '' ( P2 ) , `` Halluzinations '' ( P3 ) , `` Mannerisms posturing '' ( G5 ) `` Unusual thought content '' ( G9 ) score ≤3 `` Clinical Global Impression Severity Scale '' ( CGIS ; Guy , 1976 ) Able give inform consent Actively suicidal Serious medical illness Known noncomplience concern medication Medication clozapin Medication antidepressant mood stabilisors initiate last 6 week study enrollment Patients substance dependence nicotine caffeine within 6 month prior baseline Unability give inform consent Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>